Sickle Cell Disease News Home | Sickle Cell Disease News
3 天之前 · The kindness of blood donors makes a world of difference in my life I recently had my first blood transfusion of the year. It’s one of the most common treatments for sickle cell …
Vaso-Occlusive Crisis - Sickle Cell Disease News
2022年1月4日 · Learn more about episodes of acute pain caused by a vaso-occlusive crisis (VOC), the most common complication of sickle cell anemia.
Oxbryta's withdrawal is a setback in the fight against sickle cell
2024年10月14日 · Oxbryta’s conditional approval in 2019 by the U.S. Food and Drug Administration gave hope to many, as few treatments exist for patients with sickle cell disease. …
Stem cell transplant may be feasible for young SCD patients
3 天之前 · Stem cell transplant in young adults and adolescents with severe sickle cell disease may be a feasible option, according to a U.S. study.
News Archives – Sickle Cell Disease News
SCD patients free of VOEs after treatment with gene-editing therapy Nearly all the patients with severe sickle cell disease (SCD) who were treated with renizgamglogene autogedtemcel (reni …
Most patients free of vaso-occlusive crises for years after Casgevy
2024年12月12日 · Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for years, data show.
Most SCD patients given Lyfgenia in trials stay free of VOEs: Data
2024年12月10日 · The majority of SCD patients given Lyfgenia in clinical trials remained free of vaso-occlusive events (VOEs) following treatment, data show.
Celebrating a milestone in gene therapy for sickle cell disease
2024年11月18日 · I recently wrote about my disappointment regarding Pfizer’s decision to withdraw Oxbryta (voxelotor) from global markets as a treatment option for sickle cell disease. …
Risk of blood clots more likely with sickle cell trait, but still low
2024年9月19日 · Sickle cell carriers are at a slightly increased risk of blood clots, but the overall risk is still low, a study found.
Gates Foundation to invest in Tessera SCD gene-editing treatment
2025年1月9日 · The Gates Foundation will invest up to $50 million to support Tessera's SCD gene editing treatment, the company said.